| Archana Jain, MD | |
|
3000 Meadow Lake Dr Ste 101, Hoover, AL 35242-0302 | |
| (205) 855-5575 | |
| (205) 272-5040 |
| Full Name | Archana Jain |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 23 Years |
| Location | 3000 Meadow Lake Dr Ste 101, Hoover, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720189590 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 27545 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grandview Medical Center | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jmd Rheum, Llc | 8224403167 | 2 |
News Archive
New research from the University of Bergen (UiB), Norway, shows that a woman who's mother has urinary incontinence has a 30 percent greater chance for incontinence herself.
At last week's ABC-WIN Seminar, Prof. Dr. Michael Knauth, Director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and President-elect of the German Society of Neuroradiology, presented the European evaluation data on Separator 3D, a next-generation clot engagement device that works in conjunction with aspiration at the site of the lesion causing an acute ischemic stroke to remove the clot and restore blood flow to affected brain tissue.
A growing body of research by multiple sclerosis investigators at the University at Buffalo and international partners is providing powerful new evidence that the brain's gray matter reflects important changes in the disease that could allow clinicians to diagnose earlier and to better monitor and predict how the disease will progress.
Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis' and Debiopharm's August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.
"The cost of immunizing children in developing countries with a five-in-one vaccine is set to fall after a deal by an Indian supplier to slash the price it charges the GAVI global vaccines group," Reuters reports.
› Verified 6 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
New research from the University of Bergen (UiB), Norway, shows that a woman who's mother has urinary incontinence has a 30 percent greater chance for incontinence herself.
At last week's ABC-WIN Seminar, Prof. Dr. Michael Knauth, Director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and President-elect of the German Society of Neuroradiology, presented the European evaluation data on Separator 3D, a next-generation clot engagement device that works in conjunction with aspiration at the site of the lesion causing an acute ischemic stroke to remove the clot and restore blood flow to affected brain tissue.
A growing body of research by multiple sclerosis investigators at the University at Buffalo and international partners is providing powerful new evidence that the brain's gray matter reflects important changes in the disease that could allow clinicians to diagnose earlier and to better monitor and predict how the disease will progress.
Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis' and Debiopharm's August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.
"The cost of immunizing children in developing countries with a five-in-one vaccine is set to fall after a deal by an Indian supplier to slash the price it charges the GAVI global vaccines group," Reuters reports.
› Verified 6 days ago
| Entity Name | Affinity Physician Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366485617 PECOS PAC ID: 4385651751 Enrollment ID: O20060309000156 |
News Archive
New research from the University of Bergen (UiB), Norway, shows that a woman who's mother has urinary incontinence has a 30 percent greater chance for incontinence herself.
At last week's ABC-WIN Seminar, Prof. Dr. Michael Knauth, Director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and President-elect of the German Society of Neuroradiology, presented the European evaluation data on Separator 3D, a next-generation clot engagement device that works in conjunction with aspiration at the site of the lesion causing an acute ischemic stroke to remove the clot and restore blood flow to affected brain tissue.
A growing body of research by multiple sclerosis investigators at the University at Buffalo and international partners is providing powerful new evidence that the brain's gray matter reflects important changes in the disease that could allow clinicians to diagnose earlier and to better monitor and predict how the disease will progress.
Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis' and Debiopharm's August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.
"The cost of immunizing children in developing countries with a five-in-one vaccine is set to fall after a deal by an Indian supplier to slash the price it charges the GAVI global vaccines group," Reuters reports.
› Verified 6 days ago
| Entity Name | Jmd Rheum, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649977091 PECOS PAC ID: 8224403167 Enrollment ID: O20230407000277 |
News Archive
New research from the University of Bergen (UiB), Norway, shows that a woman who's mother has urinary incontinence has a 30 percent greater chance for incontinence herself.
At last week's ABC-WIN Seminar, Prof. Dr. Michael Knauth, Director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and President-elect of the German Society of Neuroradiology, presented the European evaluation data on Separator 3D, a next-generation clot engagement device that works in conjunction with aspiration at the site of the lesion causing an acute ischemic stroke to remove the clot and restore blood flow to affected brain tissue.
A growing body of research by multiple sclerosis investigators at the University at Buffalo and international partners is providing powerful new evidence that the brain's gray matter reflects important changes in the disease that could allow clinicians to diagnose earlier and to better monitor and predict how the disease will progress.
Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis' and Debiopharm's August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.
"The cost of immunizing children in developing countries with a five-in-one vaccine is set to fall after a deal by an Indian supplier to slash the price it charges the GAVI global vaccines group," Reuters reports.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Archana Jain, MD 3000 Meadow Lake Dr Ste 101, Hoover, AL 35242-0302 Ph: (205) 855-5575 | Archana Jain, MD 3000 Meadow Lake Dr Ste 101, Hoover, AL 35242-0302 Ph: (205) 855-5575 |
News Archive
New research from the University of Bergen (UiB), Norway, shows that a woman who's mother has urinary incontinence has a 30 percent greater chance for incontinence herself.
At last week's ABC-WIN Seminar, Prof. Dr. Michael Knauth, Director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and President-elect of the German Society of Neuroradiology, presented the European evaluation data on Separator 3D, a next-generation clot engagement device that works in conjunction with aspiration at the site of the lesion causing an acute ischemic stroke to remove the clot and restore blood flow to affected brain tissue.
A growing body of research by multiple sclerosis investigators at the University at Buffalo and international partners is providing powerful new evidence that the brain's gray matter reflects important changes in the disease that could allow clinicians to diagnose earlier and to better monitor and predict how the disease will progress.
Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis' and Debiopharm's August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.
"The cost of immunizing children in developing countries with a five-in-one vaccine is set to fall after a deal by an Indian supplier to slash the price it charges the GAVI global vaccines group," Reuters reports.
› Verified 6 days ago
Malia Bree Downing, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2279 Valleydale Rd Ste 100, Hoover, AL 35244 Phone: 205-214-7546 Fax: 205-449-2495 | |
Maria Rosario Abano Cumagun, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1870 Chace Dr Ste 160, Hoover, AL 35244 Phone: 205-733-7110 Fax: 205-733-7859 | |
Raj Vachhani, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 501 Emery Dr W, Hoover, AL 35244 Phone: 205-989-7254 | |
Dr. James Pham Ho, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1744 Napier Dr, Hoover, AL 35226 Phone: 205-261-1075 | |
Mrs. Amy L Illescas, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 10 Meadowview Dr, Hoover, AL 35242 Phone: 205-547-2323 Fax: 205-995-0955 | |
Lindsay B. Kelmenson, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 5356 Stadium Trace Pkwy Ste 200, Hoover, AL 35244 Phone: 205-444-4858 Fax: 205-444-4856 | |
Dr. Steven Bruce Hefter, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 3064 Lorna Rd, Suite E, Hoover, AL 35216 Phone: 205-822-6321 Fax: 888-414-3172 |